翰森制药(03692)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03692 翰森制药

未开盘 04-27 16:08:30

38.600

-0.760

-1.93%

最高39.360	最低38.300	成交量593.99万
今开39.360	昨收39.360	日振幅2.69%
总市值2,341亿	流通市值2,341亿	总股本60.64亿
成交额2.30亿	换手率0.10%	流通股本60.64亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03692","market":"HK","secType":"STK","nameCN":"翰森制药","latestPrice":38.6,"timestamp":1777277310006,"preClose":39.36,"halted":0,"volume":5939934,"delay":0,"changeRate":-0.019308943089430843,"floatShares":6064000000,"shares":6064000000,"eps":1.0676749271137027,"marketStatus":"未开盘","change":-0.76,"latestTime":"04-27 16:08:30","open":39.36,"high":39.36,"low":38.3,"amount":229977676,"amplitude":0.026931,"askPrice":38.6,"askSize":80000,"bidPrice":38.58,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":1.0676749271137027,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777339800000},"marketStatusCode":0,"adr":0,"listingDate":1560441600000,"exchange":"SEHK","adjPreClose":39.36,"dividendRate":0.01156,"openAndCloseTimeList":[[1777253400000,1777262400000],[1777266000000,1777276800000]],"volumeRatio":0.708546,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03692","defaultTab":"news","newsList":[{"id":"2629023400","title":"港股异动 | 创新药概念全线走低 油价上涨压制降息空间 市场关注创新药投融资前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2629023400","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629023400?lang=zh_cn&edition=full","pubTime":"2026-04-23 13:59","pubTimestamp":1776923941,"startTime":"0","endTime":"0","summary":"消息面上，地缘局势不确定性持续存在，油价上涨推升通胀预期压制降息空间。招商银行研究院发布报告称，2025年，受到全球地缘政治压力以及美联储降息节奏的影响，全球创新药融资同比下降7.1%，但Q3的融资额已恢复8%的正增长。2026年如果美伊战争影响逐渐消除，美联储仍能持续降息，创新药投融资有望持续恢复。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432508.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0502904849.HKD","UGA","VXUS","BK1589","159992","DBO","DRLL","GUSH","BK1161","LU0455707207.USD","USE","BK1583","BK1574","IEO","BNO","01530","OIH","03692","01801","DUG","LU2097828805.USD","BK4570","BK1191","09995","LU2242644610.SGD","LU2097828557.USD","DBC","OILT","LU2488822045.USD","OILU","LU2097828631.EUR","USOI","DBE","VDE","LU2097828474.EUR","LU1969619763.USD","BK1593","06978","DIG","BWET","LU2097828714.EUR","HK0000165453.HKD","PXJ","BK4585","ERX","DRIP","IXC","LU2328871848.SGD","USL","OILK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629069622","title":"长春高新2025年净利润同比下降94%；翰森制药公布抗失眠新药临床数据｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2629069622","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629069622?lang=zh_cn&edition=full","pubTime":"2026-04-22 07:02","pubTimestamp":1776812539,"startTime":"0","endTime":"0","summary":"｜2026年4月22日星期三｜NO.1长春高新2025年净利润1.55亿元，同比下降94%4月21日，长春高新披露2025年年度报告。2025年，公司实现营业收入120.83亿元，较上年同期降低10.27%；归属于上市公司股东的净利润为1.55亿元，较上年同期降低94%。公司拟向全体股东每10股派发现金红利1.60元(含税)，送红股0股，不以公积金转增股本。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604223713055256.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604223713055256.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159938","000661","09939","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629035089","title":"华源证券：维持翰森制药(03692)“买入”评级 创新管线逐步进入兑现期","url":"https://stock-news.laohu8.com/highlight/detail?id=2629035089","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629035089?lang=zh_cn&edition=full","pubTime":"2026-04-21 15:58","pubTimestamp":1776758320,"startTime":"0","endTime":"0","summary":"翰森制药公布2025年报，总收入150.28亿元，同比增长22.6%，其中创新药与合作产品销售收入123.54亿元，同比增长30.4%，占总收入82.2%；溢利55.55亿元，同比增长27.1%。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260421/20260421155617_37933.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260421/20260421155617_37933.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431241.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["161027","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628719049","title":"招银国际：医疗板块风险偏好有温和的修复 推荐翰森制药(03692)等6股","url":"https://stock-news.laohu8.com/highlight/detail?id=2628719049","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628719049?lang=zh_cn&edition=full","pubTime":"2026-04-20 11:36","pubTimestamp":1776656176,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招银国际发布研报称，MSCI中国医疗指数2026年初至今累计上涨12.3%，跑赢MSCI中国指数13.6%。近期在中国政府工作报告将生物医学列为新兴支柱产业的政策催化下，板块风险偏好有温和的修复。同时，AI制药技术突破与中国创新药出海 BD 的爆发形成双重共振，该行预期产业基本面加速向好。招商国际给予该6只股份“买入”的投资评级，目标价分别为46.41港元、113.86港元、34.87港元、10.34港元、82港元及35.46美元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430519.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","01530","BK1574","LU2488822045.USD","BK1191","LU0502904849.HKD","BK1161","LU2242644610.SGD","03692","01167","02268","HK0000165453.HKD","LU2097828714.EUR","LU2328871848.SGD","LU2097828557.USD","LU2097828474.EUR","01801","LU1969619763.USD","BK1593","159891","SG9999014674.SGD","LU0455707207.USD","LU2097828631.EUR","BK1141","LU2097828805.USD","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145722926","title":"翰森制药：4月17日发行900万股新股，占已发行股本约0.1486%","url":"https://stock-news.laohu8.com/highlight/detail?id=1145722926","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145722926?lang=zh_cn&edition=full","pubTime":"2026-04-17 18:09","pubTimestamp":1776420558,"startTime":"0","endTime":"0","summary":"翰森制药（03692）于2026年4月17日公告，根据公司于2019年5月27日批准并采纳的受限制股份单位计划，向相关激励对象发行900万股新股，占此前已发行股本约0.1486%。每股发行价为3.5788港元，涉及资金约3,220.92万港元。发行完成后，公司已发行股本增至6,064,150,070股。\n公司在公告中确认，相关发行已获得董事会正式授权并遵循联交所上市规则及相关法规规定。公告由联席公司秘书钟胜利女士签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628527734","title":"翰森制药(03692)根据受限制股份单位计划发行900万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2628527734","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628527734?lang=zh_cn&edition=full","pubTime":"2026-04-17 18:02","pubTimestamp":1776420128,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰森制药(03692)发布公告，于2026年4月17日根据公司于2019年5月27日批准及采纳的受限制股份单位的计划发行900万股本公司股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430018.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1589","BK1191","BK1583","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627503297","title":"翰森制药(03692)自研B7-H3靶向抗体-药物偶联物HS-20093联合阿得贝利单抗获NMPA纳入突破性治疗药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2627503297","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627503297?lang=zh_cn&edition=full","pubTime":"2026-04-16 19:32","pubTimestamp":1776339143,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰森制药(03692)公布，于2026年4月16日，该集团自研B7-H3靶向抗体-药物偶联物(ADC)注射用HS-20093联合阿得贝利单抗获中国国家药品监督管理局 (NMPA)批准纳入突破性治疗药物，拟定适应症为既往经过含铂化疗后进展或复发的驱动基因阴性的局部晚期或转移性非鳞状非小细胞肺癌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429534.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"翰森制药(03692)自研B7-H3靶向抗体-药物偶联物HS-20093联合阿得贝利单抗获NMPA纳入突破性治疗药物","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1191","BK1589","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626357977","title":"【券商聚焦】中泰国际重申翰森制药(03692)“增持”评级 指产品销售收入将稳健增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2626357977","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626357977?lang=zh_cn&edition=full","pubTime":"2026-04-09 10:58","pubTimestamp":1775703495,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中泰国际研报指，翰森制药 2025年收入同比增加22.6%至150.3亿元，股东净利润同比增加27.1%至55.6亿元。该机构指，公司的主要创新药中，肿瘤领域核心产品阿美替尼2025年后新增三项非小细胞肺癌方面的适应症，其中两项2025年底新增进入国家医保目录，预计销售收入将稳健增长。根据调整后DCF模型，目标价上调至45.30港元，重申“增持”评级。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/ODYzMTA4NTI1Nzg5MjIw.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODYzMTA4NTI1Nzg5MjIw.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1978486","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624697750","title":"招银国际：维持翰森制药(03692)“买入”评级 升目标价至46.41港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2624697750","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624697750?lang=zh_cn&edition=full","pubTime":"2026-04-04 19:53","pubTimestamp":1775303601,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招银国际发布研报称，维持翰森制药“买入”评级。基于强劲的产品销售预期，将目标价从45.26港元上调至46.41港元。翰森制药2025年业绩表现强劲，总收入达150.3亿元人民币(下同)，按年增22.6%，净利润55.6亿元，按年增27.1%。自2023年底以来，公司已成功将多款资产授权出海。2025年另有8款新药进入临床，对外授权已成为公司经常性的利润中心。该行表示，阿美替尼适应症扩展驱动增长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425225.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03692","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624533266","title":"海通国际：维持翰森制药(03692)“优于大市”评级 目标价45.94港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2624533266","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624533266?lang=zh_cn&edition=full","pubTime":"2026-04-03 15:04","pubTimestamp":1775199886,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，海通国际发布研报称，上调翰森制药FY26/FY27收入预测分别至170/190亿元，归母净利润预测分别至59/66亿元，以反应1)销售费用率持续改善;2)对外授权收入稳步提升并有望常态化，持续贡献利润增量。基于WACC7.5%，永续增长率3.0%(均不变)，对应目标价45.94元港元，并维持“优于大市”评级。受益于销售费用率改善，经营利润率提升4个百分点至36%。该行预计这两项适应症有望在2027年获批。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425046.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145375283","title":"翰森制药3月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1145375283","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145375283?lang=zh_cn&edition=full","pubTime":"2026-04-02 17:02","pubTimestamp":1775120563,"startTime":"0","endTime":"0","summary":"翰森制药集团有限公司于2026年4月2日发布截至2026年3月31日止的股份变动月报表。公告显示，公司于本期未有新增发行、购回或注销股份，已发行股份数量维持6,055,150,070股不变，库藏股数为0股。截至报告期末，公司确认符合香港联交所规定的公众持股量要求。报告期内未有就该可换股债券产生新增发行股份的情况。公告由联席公司秘书钟胜利女士签署。公司表示，将继续严格遵守香港联交所《上市规则》及相关法律法规的要求。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156613610","title":"异动解读 | 业绩超预期且管线催化剂丰富，翰森制药盘中大涨6.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=1156613610","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156613610?lang=zh_cn&edition=full","pubTime":"2026-04-01 16:13","pubTimestamp":1775031196,"startTime":"0","endTime":"0","summary":"翰森制药(03692)今日盘中股价大幅上涨6.09%，表现强劲。消息面上，公司2025年业绩表现超出市场预期，全年收入及净利润同比分别增长23%和27%，达到150.3亿元及55.6亿元人民币。管理层对2026年展望积极，指引产品销售和合作收入将实现双位数增长，并预计研发投入增幅超过30%。此外，公司研发管线在2026年中后期催化剂丰富，多个重点药物（如HS-20093、HS-20089等）将在年内读出关键临床数据并申请上市，今年还将有9款产品启动III期或关键注册临床。这些积极因素共同增强了市场对公司未来增长潜力的信心，推动了股价的上涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624932355","title":"交银国际：降翰森制药(03692)目标价至44.5港元 去年业绩超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2624932355","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624932355?lang=zh_cn&edition=full","pubTime":"2026-04-01 15:57","pubTimestamp":1775030223,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，交银国际发布研报称，维持翰森制药“买入”评级，下调目标价至44.5港元。　　翰森制药2025年业绩超预期，2026年创新药销售和BD延续高增长。公司全年收入和净利润同比分别增长23%及27%，各至150.3亿/55.6亿元人民币(下同)，均超该行及市场预期。　　报告指，翰森制药2026年中后期管线全面开花、催化剂丰富。今年还将有9款产品启动III期或关键注册临床。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260401/32118306.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["03692","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623630434","title":"中信里昂：维持翰森制药(03692)“优于大市”评级 目标价下调至40港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2623630434","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623630434?lang=zh_cn&edition=full","pubTime":"2026-03-31 15:50","pubTimestamp":1774943438,"startTime":"0","endTime":"0","summary":"展望未来，预计创新药增长及授权收入将继续成为公司2026年的主要增长动力。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20260331/20260331154244_27710.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260331/20260331154244_27710.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422889.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["EWH","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623371898","title":"翰森制药早盘涨超6% 全年纯利55.55亿元同比增长27.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623371898","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623371898?lang=zh_cn&edition=full","pubTime":"2026-03-31 10:44","pubTimestamp":1774925040,"startTime":"0","endTime":"0","summary":"　　翰森制药盘中涨超7%，截至发稿，股价上涨6.35%，现报35.18港元，成交额2.19亿港元。　　翰森制药日前发布2025年度业绩，该集团取得收入150.28亿元，同比增长22.57%；母公司拥有人应占溢利55.55亿元，同比增长27.07%；拟派发末期股息每股20.00港仙。值得一提的是，截至2025年12月31日止年度，创新药与合作产品销售收入约人民币123.54亿元，占收入比例约82.2%，已成为驱动集团业绩可持续增长的核心动力。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-03-31/doc-inhsvwqh2223363.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1589","BK1583","BK1191","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162487800","title":"异动解读 | 昭衍新药绩后大涨带动板块，翰森制药盘中飙升6.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=1162487800","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162487800?lang=zh_cn&edition=full","pubTime":"2026-03-31 10:00","pubTimestamp":1774922431,"startTime":"0","endTime":"0","summary":"翰森制药今日盘中大幅上涨6.17%，引起了市场的广泛关注。消息面上，港股生物医药股今日全线走高，其中昭衍新药在业绩公布后大涨逾14%，映恩生物-B升逾6%，药明生物、药明康德、泰格医药等亦升逾4%。翰森制药作为生物医药板块的重要成员，在此轮板块普涨行情中同步走强。此次生物医药板块的集体上涨，主要受到昭衍新药亮眼业绩的提振，市场情绪向好，资金流入该板块，从而带动了包括翰森制药在内的多只个股上涨。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ee4d118e55b1b421073820cd0cff0613","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623625983","title":"315亿现金“弹药”就位，翰森制药能否撬动全球创新药市场？","url":"https://stock-news.laohu8.com/highlight/detail?id=2623625983","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623625983?lang=zh_cn&edition=full","pubTime":"2026-03-30 09:51","pubTimestamp":1774835460,"startTime":"0","endTime":"0","summary":"2026年的春天，对于中国创新药行业而言，是一个检验“成色”的季节。3月29日，翰森制药（03692.HK）发布了2025年全年业绩报告。在医药行业经历资本寒冬洗礼、市场从“炒作估值”转向“验证现金流”的当下，这份财报不仅关乎一家企业，更被视为观察中国创新药头部企业能否穿越周期的窗口。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603303688387014.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603303688387014.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","159992","BK1583","BK1161","BK1574","BK1589","03692","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623356664","title":"翰森制药(03692)发布年度业绩 股东应占溢利55.55亿元 同比增长27.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623356664","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623356664?lang=zh_cn&edition=full","pubTime":"2026-03-29 19:37","pubTimestamp":1774784278,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰森制药 发布截至2025年12月31日止年度业绩，该集团取得收入150.28亿元，同比增长22.57%;母公司拥有人应占溢利55.55亿元，同比增长27.07%;每股基本盈利0.93元。拟派发末期股息每股20.00港仙。公司在中国产生销售收入的创新药共七款，形成了丰富的产品管线。截至2025年12月31日止年度，创新药与合作产品销售收入约人民币123.54亿元，占收入比例约82.2%，已成为驱动集团业绩可持续增长的核心动力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421382.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1589","BK1583","BK1191","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166728018","title":"翰森制药(03692)将于2026年7月24日派发末期股息每股0.20港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1166728018","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166728018?lang=zh_cn&edition=full","pubTime":"2026-03-29 19:35","pubTimestamp":1774784139,"startTime":"0","endTime":"0","summary":"翰森制药(03692)发布公告，董事会宣派截至2025年12月31日止年度之末期股息每股0.20港元，股东批准日期尚待公布。根据公告，公司股份将于2026年7月3日除净，合资格股东须于2026年7月6日16时30分前办理过户登记。公司将于2026年7月7日至2026年7月9日暂停办理股份过户登记手续，并于2026年7月9日为记录日。预计股息派发日为2026年7月24日。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622282910","title":"翰森制药(03692)：昕越® (伊奈利珠单抗注射液)第三项适应症获国家药监局签发药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2622282910","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622282910?lang=zh_cn&edition=full","pubTime":"2026-03-27 20:22","pubTimestamp":1774614162,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰森制药(03692)发布公告，于2026年3月25日，创新药昕越® (伊奈利珠单抗注射液)获中国国家药品监督管理局(NMPA)签发的药品注册证书，批准增加适应症：本品与常规治疗药物联合用于治疗抗乙酰胆硷受体(AChR)或抗肌肉特异性酪氨酸激酶(MuSK)抗体阳性的成人全身型重症肌无力(gMG)患者。此为昕越®获批的第三项适应症。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420787.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"翰森制药(03692)：昕越® (伊奈利珠单抗注射液)第三项适应症获国家药监局签发药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1583","03692","BK1589"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0326},{"period":"1month","weight":0.1855},{"period":"3month","weight":0.0031},{"period":"6month","weight":0.1169},{"period":"1year","weight":0.6331},{"period":"ytd","weight":0.0698}],"compareEarnings":[{"period":"1week","weight":-0.0165},{"period":"1month","weight":0.039},{"period":"3month","weight":-0.0443},{"period":"6month","weight":-0.016},{"period":"1year","weight":0.1795},{"period":"ytd","weight":0.0115}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"翰森制药集团有限公司是一家主要从事一系列药品的研发、生产及销售的投资控股公司。该公司的创新药产品包括阿美乐、豪森昕福、迈灵达、孚来美、恒沐、昕越、圣罗莱等产品。该公司的创新药产品主要应用于抗肿瘤、抗感染、中枢神经系统（CNS）疾病、代谢及其他治疗领域。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":-0.002565},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.01282},{"month":3,"riseRate":0.428571,"avgChangeRate":0.023369},{"month":4,"riseRate":0.571429,"avgChangeRate":0.04},{"month":5,"riseRate":0.666667,"avgChangeRate":0.019349},{"month":6,"riseRate":0.666667,"avgChangeRate":0.055622},{"month":7,"riseRate":0.571429,"avgChangeRate":-0.000332},{"month":8,"riseRate":0.714286,"avgChangeRate":0.01897},{"month":9,"riseRate":0.571429,"avgChangeRate":-0.033021},{"month":10,"riseRate":0.142857,"avgChangeRate":0.001586},{"month":11,"riseRate":0.714286,"avgChangeRate":0.063467},{"month":12,"riseRate":0.571429,"avgChangeRate":0.016858}],"exchange":"SEHK","name":"翰森制药","nameEN":"HANSOH PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"翰森制药(03692)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供翰森制药(03692)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"翰森制药,03692,翰森制药股票,翰森制药股票老虎,翰森制药股票老虎国际,翰森制药行情,翰森制药股票行情,翰森制药股价,翰森制药股市,翰森制药股票价格,翰森制药股票交易,翰森制药股票购买,翰森制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"翰森制药(03692)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供翰森制药(03692)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}